Smith & Nephew plc (SNN)

Market Cap	14.08B +14.1%
Revenue (ttm)	6.16B +6.1%
Net Income	625.00M +51.7%
EPS	0.72 +52.3%
Shares Out	859.08M
PE Ratio	22.52
Forward PE	14.87
Dividend	$0.75 (2.28%)
Ex-Dividend Date	Mar 27, 2026

Volume	692,404
Open	33.34
Previous Close	33.36
Day's Range	33.01 - 33.67
52-Week Range	23.91 - 38.79
Beta	0.68
Analysts	Hold
Price Target	36.25 (+9.72%)
Earnings Date	Mar 2, 2026

About SNN

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Nov 16, 1999
• Employees: 18,060
• Stock Exchange: NYSE
• Ticker Symbol: SNN
• Website: https://www.smith-nephew.com

Financial Performance

In 2025, Smith & Nephew's revenue was $6.16 billion, an increase of 6.09% compared to the previous year's $5.81 billion. Earnings were $625.00 million, an increase of 51.70%.

Analyst Summary

According to 2 analysts, the average rating for SNN stock is "Hold." The 12-month stock price target is $36.25, which is an increase of 9.72% from the latest price.

Price Target

$36.25

(9.72% upside)

Analyst Consensus: Hold